Cancer drugs are always popular biotech investments, but autoimmune disease also figures prominently in the startup ...

CAR031's global reach," including in China, as a potential treatment for liver and other solid tumors, AbelZeta CEO Tony Liu said.

The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to ...

Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...

AstraZeneca will buy AbelZeta Pharma’s 50% share of development and commercialization rights in China for a CAR-T therapy for ...

Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune system better recognize and respond to small cell lung cancer. The study aims to ...

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ...

As people age, their immune system function declines. T cell populations become smaller and can’t react to pathogens as quickly, making individuals more susceptible to a variety of infections. To try ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...